(SYK) Stryker - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 116.960m USD | Total Return: -19.4% in 12m
Avg Turnover: 897M
EPS Trend: 92.9%
Qual. Beats: -1
Rev. Trend: 99.9%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Stryker Corporation (SYK) is a global medical technology provider operating through two primary segments: MedSurg and Neurotechnology, and Orthopaedics. The company designs and manufactures specialized equipment ranging from surgical robotics and endoscopic systems to joint replacement implants and stroke intervention tools. Stryker utilizes a diversified distribution model, selling directly and via third-party dealers to healthcare facilities in over 60 countries.
As a constituent of the Health Care Equipment sub-industry, Stryker benefits from high switching costs and significant research and development requirements, which serve as barriers to entry. The business model relies heavily on the razor-and-blade strategy, where the installation of capital equipment like the Mako robotic system drives recurring revenue through specialized disposable components and service contracts.
Investors can evaluate the companys long-term valuation trends and growth metrics by visiting ValueRay. Founded in 1941 and headquartered in Michigan, Stryker maintains a dominant market position in orthopedic implants and surgical instrumentation.
- Mako robotic surgery platform adoption accelerates orthopedic implant market share gains
- Aging demographic trends sustain high demand for hip and knee replacements
- Expansion of MedSurg portfolio through strategic acquisitions drives inorganic revenue growth
- Hospital capital expenditure cycles influence high-margin surgical equipment sales volume
- Supply chain stability and raw material costs impact consolidated operating margins
| Net Income: 3.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 27.79% < 20% (prev 21.94%; Δ 5.86% < -1%) |
| CFO/TA 0.12 > 3% & CFO 5.38b > Net Income 3.34b |
| Net Debt (11.3b) to EBITDA (5.89b): 1.91 < 3 |
| Current Ratio: 2.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (386.5m) vs 12m ago 0.03% < -2% |
| Gross Margin: 63.67% > 18% (prev 61.96%; Δ 1.71% > 0.5%) |
| Asset Turnover: 54.76% > 50% (prev 50.47%; Δ 4.29% > 0%) |
| Interest Coverage Ratio: 5.53 > 6 (EBIT TTM 4.67b / Interest Expense TTM 845.0m) |
| A: 0.15 (Total Current Assets 13.3b - Total Current Liabilities 6.32b) / Total Assets 46.3b |
| B: 0.45 (Retained Earnings 20.9b / Total Assets 46.3b) |
| C: 0.10 (EBIT TTM 4.67b / Avg Total Assets 46.1b) |
| D: 0.93 (Book Value of Equity 22.3b / Total Liabilities 24.0b) |
| Altman-Z'' = 4.12 = AA |
| DSRI: 0.83 (Receivables 3.57b/3.96b, Revenue 25.3b/23.2b) |
| GMI: 0.97 (GM 61.96% / 63.67%) |
| AQI: 1.00 (AQ_t 0.63 / AQ_t-1 0.63) |
| SGI: 1.09 (Revenue 25.3b / 23.2b) |
| TATA: -0.04 (NI 3.34b - CFO 5.38b) / TA 46.3b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of June 06, 2026, the stock is trading at USD 305.66 with a total of 2,122,814 shares traded.
Over the past week, the price has changed by +0.19%,
over one month by +3.53%,
over three months by -17.28% and
over the past year by -19.44%.
Stryker has received a consensus analysts rating of 4.06. Therefore, it is recommended to buy SYK.
- StrongBuy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 389.2 | 27.3% |
P/E Trailing = 35.3523
P/E Forward = 20.3252
P/S = 4.6284
P/B = 5.0898
P/EG = 1.4528
Revenue TTM = 25.3b USD
EBIT TTM = 4.67b USD
EBITDA TTM = 5.89b USD
Long Term Debt = 14.2b USD (from longTermDebt, last quarter)
Short Term Debt = 499.0m USD (from shortLongTermDebt, last quarter)
Debt = 14.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.3b USD (calculated: Debt 14.2b - CCE 2.96b)
Enterprise Value = 128b USD (117b + Debt 14.2b - CCE 2.96b)
Interest Coverage Ratio = 5.53 (Ebit TTM 4.67b / Interest Expense TTM 845.0m)
EV/FCF = 28.05x (Enterprise Value 128b / FCF TTM 4.57b)
FCF Yield = 3.57% (FCF TTM 4.57b / Enterprise Value 128b)
FCF Margin = 18.09% (FCF TTM 4.57b / Revenue TTM 25.3b)
Net Margin = 13.21% (Net Income TTM 3.34b / Revenue TTM 25.3b)
Gross Margin = 63.67% ((Revenue TTM 25.3b - Cost of Revenue TTM 9.18b) / Revenue TTM)
Gross Margin QoQ = 63.29% (prev 65.22%)
Tobins Q-Ratio = 2.77 (Enterprise Value 128b / Total Assets 46.3b)
Interest Expense / Debt = 5.94% (Interest Expense 845.0m / Debt 14.2b)
Taxrate = 27.46% (1.26b / 4.60b)
NOPAT = 3.39b (EBIT 4.67b * (1 - 27.46%))
Current Ratio = 2.11 (Total Current Assets 13.3b / Total Current Liabilities 6.32b)
Debt / Equity = 0.64 (Debt 14.2b / totalStockholderEquity, last quarter 22.3b)
Debt / EBITDA = 1.91 (Net Debt 11.3b / EBITDA 5.89b)
Debt / FCF = 2.46 (Net Debt 11.3b / FCF TTM 4.57b)
Total Stockholder Equity = 21.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.23% (Net Income 3.34b / Total Assets 46.3b)
RoE = 15.22% (Net Income TTM 3.34b / Total Stockholder Equity 21.9b)
RoCE = 12.92% (EBIT 4.67b / Capital Employed (Equity 21.9b + L.T.Debt 14.2b))
RoIC = 6.33% (NOPAT 3.39b / Invested Capital 53.6b)
WACC = 7.45% (E(117b)/V(131b) * Re(7.83%) + D(14.2b)/V(131b) * Rd(5.94%) * (1-Tc(0.27)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.66 | Cagr: 0.30%
[DCF] Terminal Value 77.97% ; FCFF base≈4.17b ; Y1≈4.78b ; Y5≈7.04b
[DCF] Fair Price = 247.0 (EV 106b - Net Debt 11.3b = Equity 94.7b / Shares 383.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 92.90 | EPS CAGR: 9.91% | SUE: -2.41 | # QB: -1
Revenue Correlation: 99.86 | Revenue CAGR: 10.45% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=3.49 | Chg30d=+0.79% | Revisions=+4% | Analysts=22
EPS next Quarter (2026-09-30): EPS=3.68 | Chg30d=+3.39% | Revisions=+77% | Analysts=22
EPS current Year (2026-12-31): EPS=14.99 | Chg30d=+0.16% | Revisions=-42% | GrowthEPS=+9.9% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=16.72 | Chg30d=-0.15% | Revisions=-36% | GrowthEPS=+11.6% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: +77%